Compare NVEC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | GYRE |
|---|---|---|
| Founded | 1989 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.0M | 606.4M |
| IPO Year | 1995 | 2004 |
| Metric | NVEC | GYRE |
|---|---|---|
| Price | $100.89 | $6.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 130.2K | 46.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | ★ 0.96 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $26,331,218.00 | $275,000.00 |
| Revenue This Year | N/A | $19.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $81.12 | ★ N/A |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $57.21 | $5.44 |
| 52 Week High | $135.00 | $9.42 |
| Indicator | NVEC | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 51.09 |
| Support Level | $78.89 | $5.78 |
| Resistance Level | $111.64 | $6.66 |
| Average True Range (ATR) | 5.29 | 0.29 |
| MACD | -2.19 | -0.02 |
| Stochastic Oscillator | 2.41 | 21.84 |
NVE Corp is engaged in developing and selling devices that use spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store, and transmit information. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.